AbbVie, Regenxbio enter partnership on eye therapy

Sept 13 Reuters - AbbVie and Regenxbio Inc entered a partnership to develop and commercialize RGX - 314, a gene therapy candidate for the treatment of chronic retinal diseases, which would give the latter an upfront payment of $370 million.

The pharmaceutical companies said that Regenxbio could potentially receive up to $1.38 billion in milestone payments on Monday.

RGX - 314 is currently involved in a pivotal trial for the treatment of ourt age-related macular degeneration AMD, an eye disorder that causes blurred vision or a blind spot in the visual field. The trial is testing the RGX - 314 presented under the retina.

It is also being studied in patients with wet AMD and diabetic retinopathy in two separate mid-stage clinical trials using a different type of delivery.

Regenxbio will be responsible for the completion of the ongoing studies of RGX - 314. Both companies will share the costs of additional trials of RGX - 314, they said.

AbbVie will lead the commercial development and clinical development of RGX - 314 globally.